Andrea Charles | 11/04/2012
With budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition. But the challenges remain: how do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible?Jorrit J. Hornberg, PhD Head of Section In Vitro Studies, Exploratory Toxicology at Lundbeck, speaks to Andrea Charles fro...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma & Health 2024
September 10 - 12, 2024
Düsseldorf, Germany
Register Now |
View Agenda |
Learn More
Temperature Control and Logistics North America Summit
September 10 - 12, 2024
Falls Church, VA
Register Now |
View Agenda |
Learn More